Bifurcation Disease What Do We Know, What Should We Do? by Latib, Azeem & Colombo, Antonio
B
W
A
M
T
t
o
t
s
s
c
t
2
A
i
b
r
t
s
u
t
d
t
s
e
b
s
(
p
t
e
c
s
a
(
w
F
I
C
M
M
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 1 , N O . 3 , 2 0 0 8
© 2 0 0 8 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / 0 8 / $ 3 4 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 0 7 . 1 2 . 0 0 8ifurcation Disease
hat Do We Know, What Should We Do?
zeem Latib, MB BCh,*‡ Antonio Colombo, MD*†
ilan, Italy; and Cape Town, South Africa
he percutaneous treatment of coronary bifurcations has moved past an important milestone in that
he 1- versus 2-stent debate appears to have been resolved. The provisional approach of implanting
ne stent on the main branch should be the default approach in most bifurcations lesions. Selection of
he most appropriate strategy for an individual bifurcation is important. Some bifurcations require 1
tent, whereas others require the stenting of both branches. Irrespective of whether a 1- or 2-stent
trategy is chosen, the results after bifurcation percutaneous coronary intervention (PCI) have dramati-
ally improved. Dedicated bifurcation stents are an exciting new technology that may further simplify
he management of bifurcation PCI and change some of these concepts. (J Am Coll Cardiol Intv
008;1:218–26) © 2008 by the American College of Cardiology Foundationt
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tpproximately 15% to 20% of percutaneous coronary
nterventions (PCIs) are performed to treat coronary
ifurcations (1,2); PCIs in these circumstances are
enowned for being technically challenging and his-
orically have been associated with lower procedural
uccess rates and worse clinical outcomes than when
sed to treat nonbifurcation lesions. In addition,
here has also been a large amount of uncertainty and
ebate as to the most appropriate strategy when
reating bifurcations. This debate has predominantly
temmed from a lack of randomized data, which may
xplain why therapeutic strategies have been largely
ased on the personal clinical experiences of highly
killed operators practicing in high-volume centers
3). However, in the last few years, significant im-
rovements have occurred in our understanding and
reatment of bifurcations: 1) introduction of drug-
luting stents (DES); 2) numerous randomized-
ontrolled trials specifically in bifurcations; 3) a more
elective usage of 2 stents as intention-to-treat; 4) the
cceptance of a suboptimal result in the side branch
SB), i.e., one stent only on the main branch (MB),
hen treating bifurcations involving a minor SB; 5)
rom the *Interventional Cardiology Unit, San Raffaele Scientific
nstitute and †Interventional Cardiology Unit, EMO Centro Cuore
olumbus, Milan, Italy; and ‡Division of Cardiology, Department of
edicine, University of Cape Town, Cape Town, South Africa.banuscript received November 27, 2007; accepted December 10, 2007.he better performance of any 2-stent technique (high
ressure post-dilation, kissing inflation, and possibly
ntravascular ultrasound); and 6) the understanding
hat a different approach and result should be ac-
epted for bifurcations involving the left main com-
ared with other bifurcations.
As a result of these changes, the outcomes after
ifurcation PCI have improved considerably and,
urrently, approximate those of nonbifurcation PCI
4). In this review, we highlight what we currently
now about the treatment of bifurcation disease and,
ased on this knowledge, we offer our recommenda-
ions and a practical approach to bifurcation inter-
ention.
ES Versus Bare-Metal Stents (BMS)
he effectiveness of DES in reducing restenosis
nd revascularization in less-complex lesions has
een extended to the coronary bifurcation. The
nly randomized data that compares DES and
MS comes from a subanalysis of the SCAND-
TENT (Stenting Coronary Arteries in Non-
tress/Benestent Disease) trial, which examined a
otal of 126 patients with bifurcation lesions
reated with sirolimus-eluting stents (SES) or
MS (5). In 55% of the SES cohort and 53% of
he BMS cohort, stents were implanted in both
ranches of the bifurcation. Implantation of SES
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219as associated with significant reductions in restenosis rates
t the MB (4.9% vs. 28.3%, p  0.001) and SB (14.8% vs.
3.4%, p  0.001), as well as major adverse cardiac events
MACEs) during the 7-month follow-up period (9% vs.
8%, p  0.009).
Similarly, registry studies have shown marked reductions in
ACE and target lesion revascularization (TLR) rates com-
ared with historical BMS controls. These reductions occurred
rrespective of whether a 1-stent (MACE: 5.4% vs. 38%; TLR:
.4% vs. 36%) or 2-stent (MACE: 13.3% vs. 51%; TLR: 8.9%
s. 38%) strategy was used (6,7). As a result, DES have become
he preferred stent platform for the treatment of coronary
ifurcations. However, BMS are still indicated when there are:
) contraindications to prolonged dual antiplatelet therapy; 2)
n the setting of bifurcation stenting in acute myocardial
nfarction due to concerns about a higher risk of stent throm-
osis (ST) (8); or 3) in short lesions in the MB of non-true
ifurcations.
- Versus 2-Stent Strategy
here are now 5 randomized studies (1,9–12) available that
ompare a provisional approach of implanting 1-DES in the
B only versus a 2-DES approach of implanting a DES on
oth the MB and SB of the bifurcation, the results of which are
ummarized in Table 1. It is apparent from these data that
outine stenting of both branches offers no clear advantage over
provisional strategy of stenting the MB only with balloon
ngioplasty of the SB, with regard to restenosis in the MB or
Bs or in repeat bifurcation revascularization. A 2-DES
pproach is associated with procedures that are longer, with
ore fluoroscopy time and contrast volumes, and a greater rate
f procedure-related biomarker release (1).
Thus, the contemporary treatment of bifurcation lesions
as finally overcome a major crossroad: 1 versus 2 stents.
here are bifurcation lesions that require 1 stent as a default
reatment with a second stent implanted on the SB if a
uboptimal result has been obtained and an optimal result is
eeded; most bifurcation lesions can be placed in this group.
ikewise, there are bifurcation lesions in which 2 stents
MB and SB stenting) need to be implanted as intention-
o-treat because of the characteristics of the lesion and the
istribution of the SB. The distinction between these
trategies is that, in the 1-DES approach, the operator may
e willing to accept a suboptimal result in the SB provided
hat Thrombolysis In Myocardial Infarction (TIMI) flow is
ormal and the SB has limited clinical relevance regarding
erritory of distribution.
However, how do we define what a suboptimal result in the
B is? It is important to note that a major difference between
he 5 randomized trials in Table 1 was the definition of a
uboptimal result in the SB. This definition has a major impact
oth on the crossover rate from a 1-DES to a 2-DES strategy
nd the restenosis rate in SBs treated with a provisional wtrategy. In the Sirius Bifurcation study (9), a residual stenosis
f 50% in the SB was considered unacceptable, which
xplains the very high crossover rate of 51.2%. In contrast, in
he Nordic study (1), the residual SB stenosis was irrelevant,
nd the SB had just to remain open with TIMI flow grade0.
his information clarifies why the greatest (19.2%) SB reste-
osis rate with a 1-DES approach was observed in this study.
lthough it may be satisfactory to accept a suboptimal result
ith TIMI flow grade 1 in a small obtuse marginal branch,
uch a result is not acceptable when treating a distal left main
ifurcation or a bifurcation involving a large diagonal branch.
n examining the recent CACTUS (Coronary Bifurcation
pplication of the Crush Technique Using Sirolimus-Eluting
tents) (12) and Bad Krozingen (11) bifurcation studies, a
ore realistic figure is that in 20% to 30% of bifurcations
reated with a provisional strategy,
second stent will have to be
mplanted on the SB.
Additionally, there appears to
e increasing evidence that the
ttempt to get an optimal angio-
raphic result with minimal resid-
al stenosis in the SB may not be
hysiologically important. This
oncept is especially important in
maller SBs, where the majority of
ngiographically significant SB le-
ions are demonstrated to be not
unctionally significant by frac-
ional flow reserve (FFR) analysis
13). Koo et al. (13) performed
FR measurements on 94 jailed
B lesions after stent implantation
n the MB. No lesion with a
50% and 75% stenosis had a
FR 0.75. Among 73 lesions
ith 75% stenosis, only 20 le-
ions were functionally significant.
urthermore, smaller SBs are less
ikely to result in angina if a residual stenosis is left untreated or
f restenosis occurs (14,15). However, this should not diminish
he importance of protecting SBs with guidewires to prevent
heir closure, because it has been shown that SB compromise is
ot inconsequential. Occlusion of SBs 1 mm can be associ-
ted with 14% incidence of myocardial infarction (16), and SB
2 mm) compromise during a provisional approach can be
ssociated with a large periprocedural myocardial infarct (17).
n the end, the operator needs to decide how important an
ptimal result is in that particular SB for that particular patient.
An important observation from the randomized data in
able 1 is that the clinical outcomes, in particular revascu-
arization rates, after bifurcation PCI have improved con-
iderably. In the Nordic study, TLR was extremely low and
Abbreviations
and Acronyms
BMS  bare-metal stent
DES  drug-eluting stent
FFR  fractional flow
reserve
FKI  final kissing inflation
IVUS  intravascular
ultrasound
MACE  major adverse
cardiac event
MB  main branch
PCI  percutaneous
coronary intervention
SB  side branch
SES  sirolimus-eluting
stent
ST  stent thrombosis
TIMI  Thrombolysis In
Myocardial Infarction
TLR  target lesion
revascularizationas based solely on clinical adjudication, which was per-
Table 1. Main Studies Comparing Provisional Stenting to Both Branch Stenting With Drug-Eluting Stents in Coronary Bifurcations: The First 5 Studies Are Randomized Studies,
Whereas the Last One Is a Large Registry
Author, Year
(Ref. #) Aim
No. of
Patients Follow-Up
1-Stent Group 2-Stent Group
Angiographic
Follow-Up, %
Pre-RVD,
mm
Restenosis,
%
TLR,
%
ST,
%*
Angiographic
Follow-Up, %
Pre-RVD,
mm
Restenosis,
%
TLR,
%
ST,
%*
Crossover
From 1
Stent to 2
Stents, % SB Stented IfMB SB MB SB MB SB MB SB
Colombo et al.,
2004 (9)
Both branches vs.
provisional
stenting
85 6 months 84.1 2.6 2.1 4.8 14.2 4.5 0 95.4 2.6 2.1 5.7 21.8 9.5 4.7 51.2 50% residual
stenosis in SB
Pan et al., 2004
(10)
Both branches vs.
provisional
stenting
91 6 months 87 3.0 2.5 2.4 4.9 2.1 0 89 2.9 2.5 10.3 15.4 4.5 2.2 2.1 50% residual
stenosis AND TIMI
ﬂow3
Steigen et al.,
2006 (1)
Crush, culotte, Y vs.
provisional
stenting
413 6 months 72.9 3.3 2.6 4.6 19.2 1.9 0.5 75.7 3.3 2.6 5.1 11.5 1 0 4.3 TIMI ﬂow  0 after SB
dilation
Ferenc et al.,
2007 (11)
Reverse crush vs.
provisional
stenting
202 12 months 95 3.08 2.39 7.3 3.2 10.9 1.0 95 3.09 2.38 7.3 11.5 8.9 2.0 18.8 60% stenosis and/or
ﬂow-limiting
dissection
CACTUS;
Colombo et
al., 2007 (12)
Crush vs.
provisional
350 Only 30 day
available
currently
N/A 2.74 2.16 N/A N/A N/A 0.5 N/A 2.85 2.30 N/A N/A N/A 1.7 31 50% stenosis and/or
ﬂow-limiting
dissection
§ARTS II
Substudy
2007 (4)
Different subgroup
analyses:
bifurcations vs.
non bifurcations
324 patients
with 465
bifurcations
1 yr N/A N/A N/A N/A N/A 9.9 1.5 N/A N/A N/A N/A N/A 4.9 1.6 N/A N/A
*Stent thrombosis defined as per definition in study.
1-stent groupbifurcation lesions treatedwithprovisional stent technique; 2-stent groupbifurcation lesions treatedwithbothbranch stenting technique;MBmainbranchof thebifurcation; N/Anot available or not applicable; RVD reference vessel diameter;
SB side branch of the bifurcation; ST stent thrombosis; TIMI Thrombolysis In Myocardial Infarction; TLR target lesion revascularization.
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221ormed 2 months before angiographic follow-up, possibly
eutralizing the oculostenotic reflex on repeat revasculariza-
ion. The apparent disparity between restenosis rates (1-
ES  22.5%; 2-DES  16% for the bifurcation overall)
nd repeat revascularization (1-DES  1.9%; 2-DES 
.0%) observed in this study may suggest that majority of
hese SB restenoses were clinically silent and possibly
rrelevant. These improved outcomes in bifurcation PCI
ere also confirmed in the ARTS II (Arterial Revascular-
zation Therapies Study II) study (4), in which outcomes at
year were similar in bifurcation and nonbifurcation lesions
hat were treated with SES implantation (major adverse
ardiac and cerebrovascular event 11.0% vs. 13.3%, p 
.46; revascularization 7.8% vs. 9.0%, p  0.66). Both of
hese studies also confirm that outcomes in bifurcation PCI
re very good if only clinically driven angiographic
ollow-up is performed.
-DES Techniques
he most important studies in which a 2-DES technique was
sed to treat a bifurcation are summarized in Table 2 (18–26).
iemela et al. (26) have performed the only randomized study
Table 2. Main Studies Evaluating Drug-Eluting Stents in Coronary Bifurcati
Which Is a Randomized Study
Author, Year
(Ref. #) Aim
No. of
Bifurcations Follow-Up
Restenosis, %
MB SB
Ge et al., 2005
(19)
Crush with
FKI vs.
without
181 9 months 8.9 11.1†
Hoye et al.,
2006 (18)
Crush 241 9 months 6.4 9.6†
Moussa et al.,
2006 (20)
Crush 120 6 months N/A N/A
Sharma et al.,
2005 (21)
Simultaneous
kissing
stents
200 9  2
months
N/A N/A
Galassi et al.,
2007 (22)
Mini-Crush 52 8 months 12.2 2.0
Burzotta et al.,
2007 (23)
T-stenting
and small
protrusion
73 9 months N/A N/A
Ge et al., 2006
(24)
Crush vs. T 182 1 yr 16.2 19.2
Kaplan et al.,
2007 (25)
Culotte vs. T 80 9 months N/A N/A
Niemela et al.,
2007 (26)
Culotte vs.
Crush
425 6 months N/A N/A
*Stent thrombosis defined as per definition in study and does not include intraprocedural stent thr
FKI final kissing inflation; other abbreviations as in Table 1.omparing 2 different 2-DES techniques (Culotte vs. Crush). bhe study showed no difference in clinical outcomes at 6
onths but was limited by the short follow-up period, lack of
ngiographic follow-up, and significantly less final kissing
nflation (FKI) in the crush group. Thus, there are insufficient
ata to recommend one technique over another based solely on
ower event rates. The decision is based rather on the anatomy
f the bifurcation and the familiarity and competence of the
perator with a specific technique. However, it is apparent that
ptimal performance of 2-DES techniques is important and
mproves outcomes. An example is the importance of FKI in
educing late loss and restenosis, especially at the SB, which
as been repeatedly demonstrated and has now become stan-
ard in the performance of all 2-DES techniques (18,19).
here are other important technical factors that may contrib-
te to optimizing outcomes when performing 2-DES tech-
iques, such as high-pressure SB inflation, the use of noncom-
liant balloons, selection of correct balloon size for FKI, and
he use of intravascular ultrasound (IVUS).
n Individualized Approach to Bifurcation PCI
ifurcations vary not only in anatomy (plaque burden,
ocation of plaque, angle between branches, diameter of
ith MB and SB Stenting: All Are Observational Except for the Last,
TLR, % ST, %*
Restenosis, %
TLR, % ST, %*MB SB
FKI No FKI
9.5 2.6 15.5 37.9† 24.6 3.0
A 9.7% overall 4 10 41.3† N/A 9.7% overall 4.2
1.3% overall 1.7% overall N/A N/A 11.3% overall 1.7%
overall
4 1 N/A N/A N/A N/A
12.2 2.2 N/A N/A N/A N/A
6.8 1.4 N/A N/A N/A N/A
sh (n  121) T-stenting (n  61)
14† 1.6 13 26.1 31.1† 0
otte (n  45) T-stenting (n  35)
8.9† 2.2 N/A N/A 27.3† 0
sh (n  210) Culotte (n  215)
TVR  3.3 1.9 N/A N/A TVR  3.3 1.4
is. †p 0.05 for difference between the 2 groups.ons W
N/
1
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ombosranches, bifurcation site) but also in the dynamic changes
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222n anatomy during treatment (plaque shift, dissection). As a
esult, no 2 bifurcations are identical, and no single strategy
xists that can be applied to every bifurcation. Thus, the
ore important issue in bifurcation PCI is selecting the
ost appropriate strategy for an individual bifurcation and
ptimizing the performance of this technique.
Although there are currently at least 6 different classifi-
ations of bifurcation lesions (27–32), the most commonly
sed one is the Medina classification (Fig. 1). Practically,
he most important distinction is to divide bifurcation
esions into: “true” bifurcations (i.e., Medina 1.1.1, 1.0.1,
.1.1) where MB and SB are both significantly narrowed
50% diameter stenosis) and “non-true bifurcations,”
hich include all the other lesions involving a bifurcation.
on-true bifurcations should always be treated with a
-DES strategy. Other important elements to consider that
re not inherent in the bifurcation classifications include:
he extent of disease on the SB (limited to the ostium or
nvolving the vessel beyond the ostium), its size (2.5 mm
f reference diameter), angle, and distribution. The previous
ssumption stating that most true bifurcation lesions need 2
tents whereas the other bifurcation lesions require one stent
s probably obsolete. Current approaches may require 2
tents in approximately 30% of the true bifurcations unless
ocated on the left main coronary artery, where this percent-
ge may be as great as 50%. These concepts may change
hen dedicated bifurcation stents become widely available.
The objective of bifurcation PCI is to end the procedure
ith both branches open and an optimal result in the MB.
his statement is completely different if the SB is an
mportant vessel sometimes as important as the MB.
Figure 1. Medina Classification of Bifurcation Lesions
In the Medina classiﬁcation (25), a binary value (1,0) is given to each of the
3 components of a bifurcation (main branch proximal, main branch distal,
and the side branch) according to whether each of these segments is com-5
promised (1) or not (0).mong the questions the operator has to answer at the
eginning of the procedure are: 1) How important the SB is
or that patient and for that specific anatomy? 2) The size
nd extent of disease in the SB. If the SB has ostial disease,
his condition is different from disease extending beyond the
stium. In true bifurcations, we like to consider a special
roup in which the disease of the SB extends from the
rigin to 10 to 20 or more mm distally which, in our
xperience, occurs in approximately 30% of bifurcations that
e treat.
A practical approach to bifurcation PCI can be summa-
ized here. Two wires should be placed in most bifurcations,
nd the SB wire should be “jailed” in the majority after the
eployment of the stent on the MB. This approach is
mportant in protecting the SB from closure as the result of
laque shift and/or stent struts during MB stenting. The
ailed SB wire also facilitates rewiring of the SB (if SB
ost-dilation/stenting or FKI is needed, or if the SB
ccludes) by widening the angle between the MB and SB
33,34), by acting as a marker for the SB ostium, and by
hanging the angle of SB take-off. Interestingly, in the
rench multicenter TULIPE (Provisional T-stenting for
oronary Bifurcation Lesion Prospective Evaluation) study,
he absence of this jailed wire was associated with a greater
ate of reinterventions during follow-up (34). There is no
eed to remove the jailed wire during high-pressure stent
ilation in the MB. It is preferable to avoid jailing hydro-
hilic guidewires because there is a risk of removing the
olymer coating. Accurate handling of the guiding catheter
o prevent migration into the ostium of the coronary vessel
ill allow removal of the jailed wire.
Two stents as “intention-to-treat” should be the tech-
ique when the disease in the SB extends beyond the ostium
nd when the diameter and territory of distribution are
elatively large. There are no solid data to support the
upposition that 2 stents are more thrombogenic than one,
hat is, provided correct stent placement has been performed
nd compliance with antiplatelet therapy is maintained. In
ll other conditions, SB provisional stenting should be the
rocedure of choice.
Our individualized approach to treating a true bifurcation
s dictated by the SB. It is summarized in Figure 2 and
etailed in the following sections.
B is not suitable (too small) for stenting or clinically irrele-
ant AND has ostial or diffuse disease. The strategy pro-
osed in these bifurcations is the “keep it open” strategy,
hich is performed as follows:
. Wire both branches.
. Dilate MB if needed but not SB.
. Stent MB and leave wire in the SB.
. Perform post-dilation of the MB with jailed wire in
the SB.. Do not rewire SB or postdilate SB.
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223This “jailed wire” strategy allows protection of a SB that
ay not require treatment but where the need to maintain
atency is important. This strategy can be used as a
tand-alone technique or as part of the provisional strategy
hen the operator may need to eventually dilate or stent the
B. This approach of just “keep it open” for the SB was the
trategy used in the provisional stenting group of the Nordic
tudy.
B is suitable for stenting AND SB has minimal disease or
isease at the ostium only. In these bifurcations the “pro-
isional” strategy is used. This strategy is quick, safe, easy to
erform, and has been shown to be associated with results
hat are comparable with a more complex approach. A 6F
uide catheter is generally used but, if Xience V (Abbott
ascular Devices, Redwood City, California) or Promus
Boston Scientific, Natick, Massachusetts) are to be im-
lanted, a 7-F guide is preferred. The provisional approach
s performed as follows:
. Wire both branches.
. Predilate the MB and the SB as required; many SBs
without significant disease do not require predilation.
. Stent the MB, leaving the SB wire in place. If the
angiographic results in MB and SB are satisfactory, the
procedure is complete and the SB wire jailed behind the
MB stent struts can be removed gently.
. Rewire SB and then remove jailed wire. In our experi-
ence, recrossing into the SB through the MB stent struts
is usually possible using the Rinato-Prowater wire (Asahi
Intecc Co. Ltd., Nagoya, Japan/Abbott Vascular De-
vices) and in extremely difficult cases the ACE fixed wire
balloon (Boston Scientific). In difficult situations, we
Figure 2. Proposed Algorithm for Treating Coronary Bifurcations
This approach to bifurcation stenting is based on whether both branches
have signiﬁcant disease, the diameter of the side branch (SB) and the
extent of disease in the SB. MB  main branch.have also successfully used the Pilot 150 (Abbott Vascu- alar Devices/Guidant Corporation, Santa Clara, Califor-
nia) or the Miracle 3 or 4.5 gm (Asahi Intecc Co.
Ltd./Abbott Vascular Devices) wires. The jailed wire in
the SB should always be left in place as a marker until
complete re-crossing has been done.
. SB balloon dilation and FKI. FKI is mandatory if the SB
is dilated through the MB stent struts to correct MB
stent distortion and expansion (34,35).
. If the result remains unsatisfactory (suboptimal result,
plaque shift with 75% residual stenosis or TIMI flow
grade 3, in a SB 2.5 mm) or SB balloon dilation is
complicated by a flow-limiting SB dissection, then SB
stenting should be performed. A second stent in the
SB may only be required in 20% to 30% of cases
(Table 1).
There is uncertainty as to whether FKI is mandatory
hen a provisional approach is used and there are no data to
upport it. Theoretically, and from benchmark studies, FKI
as the advantage of opening stent struts that potentially
an scaffold the SB ostium and, thus, facilitate future access
o the SB. There is also concern that stenting across a
ifurcation without opening the stent struts into the SB
esults in “malapposed” struts across the SB ostium that are
ot endothelialized. The use of FKI should only be per-
ormed in bifurcations in which the SB is suitable for
tenting should dissection occur.
B is suitable for stenting AND has disease extending beyond
ts ostium. A 2-stent technique is suggested in these cases.
e recommend using an 8-Fr guiding catheter.
. Wire both branches.
. Dilate MB and SB if needed.
. Perform crush, culotte, V-stent, simultaneous kissing
stents, or T-stenting.
. If crush is performed, rewire SB and perform high-
pressure SB dilation (2-step kiss).
. Use FKI always.
A detailed description of the various 2-stent techniques
as been previously published (36). Apart from familiarity
ith a technique, the angle of the SB from the bifurcation
s an important determinant of the technique chosen. In
ifurcations with angles close to 90°C, T-stenting provides
omplete coverage of the SB ostium but should be avoided
ith more acute angles where the culotte or crush tech-
iques are a better choice.
he Role of IVUS in Bifurcation PCI
ntravascular ultrasound may provide valuable insights into
ur understanding of bifurcation PCI, as illustrated by an
VUS study of the Crush technique (37). The use of IVUS
emonstrated that incomplete crushing (i.e., incomplete
pposition of the 3 layers of MB and SB stent struts) and
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224stial SB stent underexpansion are common and often not
uspected angiographically. As a result of this study and our
wn observations, we modified our technique by using
oncompliant balloons to perform high-pressure SB infla-
ion before FKI, thereby performing a 2-step kiss.
Unfortunately, other than this study, few other experi-
nces have been published regarding the role of IVUS in
ifurcation lesions, and what follows come entirely from the
irect experience of the authors during the performance of
prospective registry (INSIDE) presented by Ricardo Costa
t Transcatheter Cardiovascular Therapeutics 2007 (38).
he authors of this registry enrolled 31 patients with 35
ifurcations in which IVUS-guided stenting was performed
n the MB and/or SB. Angiographic follow-up has been
ow completed in most of the patients. This study found
hat an optimal IVUS result at the end of the procedure was
he main factor associated with the absence of restenosis on
he MB or SB. We also noticed that the need for 2 stents
as mainly confined to lesions with a large plaque burden at
he baseline IVUS.
An interesting finding from this early experience was that
n optimal angiographic result on the SB was frequently not
upported by an adequate IVUS evaluation. An optimal
VUS result was finally obtained after dilation with a larger
alloon and at greater pressure. These observations remain
reliminary because of the small number of patients evalu-
ted. Only a prospective study with set criteria may be able
o fully evaluate this area. Despite these limitations, the
uthors strongly believe that IVUS guidance should be used
hen implanting stents in bifurcation lesions involving a
arge amount of myocardium at jeopardy.
djunctive Procedures
n considering adjunctive procedures such as rotational or
irectional atherectomy, there are no data to support the
uperiority of these devices in bifurcation lesions. Plaque
emoval with directional atherectomy, in particular, may
eem a rational choice in bifurcation lesions. Unfortunately,
n the AMIGO (Atherectomy before Multi-Link Improves
umen Gain and Clinical Outcomes) trial, a dedicated,
andomized trial in which researchers compared BMS
ersus. directional atherectomy before stenting, the results
ailed to show any superiority for directional atherectomy,
ven in the subgroup of lesions involving a bifurcation (39).
owever, it may be that such niche technology only has a
avorable cost-benefit ratio when used selectively and ap-
ropriately, as in the PERFECT (PrE Rapamycin-eluting
tent FlExi-CuT) registry (40,41).
tent Thrombosis
tenting bifurcation lesions with DES are associated with
n increased risk of ST. This risk is not greater when 2 (tents versus 1 stent is used (1,42,43). In some reports, the
se of 2 stents has been associated with an increased risk of
T in the setting of acute myocardial infarction (8). A study
y Hoye et al. (18) reported a ST rate of 4.3% with the crush
echnique. However, of the 10 patients who had a ST, only
were documented angiographically, and 4 had discontin-
ed dual-antiplatelet therapy within 7 months of the pro-
edure (18). The Nordic study is reassuring in that only one
atient had a definite ST, and this patient was treated with
stent. In the ARTS II study, 5 cases of ST (1.5%) occurred
n a total of 465 bifurcations in 324 patients treated with
ES. Four of these were subacute ST, with 3 of the
ifurcation lesions having had a poor angiographic result at
he end of the procedure and the only case of late ST
ccurring in a nonbifurcation lesion (4). Thus, there is
urrently no convincing evidence to suggest that we should
efrain from using DES in bifurcations or that a 2-stent
trategy is associated with a greater risk of ST. Despite these
tatements, we should take into consideration the fact that
mplanting 2 stents always demands more attention and
xpertise to obtain the best result in both MB and SB.
edicated Bifurcation Stents
hus far, the main advantage of most dedicated bifurcation
tents is to allow the operator to perform the procedure on
bifurcation lesion without the need to rewire the SB.
edicated bifurcation stents can be broadly divided into 2
ategories:
. Stents for provisional SB stenting that facilitate or
maintain access to the SB after MB stenting and do not
require recrossing of MB stent struts (e.g., Petal, Boston
Scientific; Invatec, Invatec S.r.l., Brescia, Italy; Antares,
Trireme Medical Inc., Pleasanton, California; Y-med
Sidekick, Y-med Inc., San Diego, California; Nile
CroCo, Minvasys, Genevilliers, France; Multi-link
Frontier, Abbott Vascular Devices/Guidant Corpora-
tion). These stents allow placement of a second stent on
the SB if needed.
. Stents that usually require another stent implanted in the
bifurcation (e.g., Sideguard, Cappella Inc., Auburndale,
Massachusetts); Tryton, Tryton Medical, Newton, Mas-
sachusetts; Axxess Plus, Devax, Irvine, California). The
Tryton and Sideguard are designed to treat the SB first
and require recrossing into the SB after MB stenting for
FKI. The Axxess Plus is the exception as it is implanted
in the proximal MB at the level of the carina and does
not require re-crossing into the SB but may require the
additional implantation of 2 further stents to completely
treat some types of bifurcation lesions.
The Axxess Plus stent is the first of these dedicated
ifurcation stents designed to elute an antirestenostic drug
biolimus A9). The Axxess Plus stent is a self-expanding,
n
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225ickel-titanium, conically shaped stent that is placed at the
evel of the carina. Grube et al. (44) have recently published
he results of the prospective multicenter single-arm Axxess
lus trial in which 139 patients were enrolled. The Axxess
tent was successfully implanted on the MB in 93.5% of
ases, with 80% of the patients receiving an additional stent
o the MB or SB. At 6 months’ follow-up, the in-stent late
oss was 0.09  0.56 mm, and the overall TLR was 7.5%,
hich confirmed the feasibility and efficacy of a dedicated
ifurcation stent. A number of the other dedicated bifurcation
tents are currently undergoing “first in human,” studies and
he results of clinical studies using these devices are eagerly
waited. These dedicated bifurcation stents are a promising
nnovation in the percutaneous management of bifurcation
isease but larger studies with control groups demonstrating
heir clinical applicability and benefit are required before
hey are widely incorporated into daily practice (3).
onclusions
he percutaneous treatment of coronary bifurcations has
oved past an important milestone in that the 1-stent
ersus 2-stent debate appears to have been resolved. The
rovisional approach of implanting one stent on the MB
hould be the default approach in most bifurcations lesions.
election of the most appropriate strategy for an individual
ifurcation is important. There are some bifurcations that
equire 1 stent, whereas others require the stenting of both
ranches. Irrespective of whether a 1- or 2-stent is strategy
hosen, the results after bifurcation PCI have dramatically
mproved. Dedicated bifurcation stent are an exciting new
echnology that may further simplify the management of
ifurcation PCI and change some of these concepts.
eprint requests and correspondence: Dr. Antonio Colombo,
MO Centro Cuore Columbus, Via Buonarroti 48, 20145 Milan,
taly. E-mail: info@emocolumbus.it.
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